Skip to main content
Top

22-09-2023 | Uveitis | REVIEW

Management of Blau syndrome: review and proposal of a treatment algorithm

Authors: Hanene Lassoued Ferjani, Lobna Kharrat, Dorra Ben Nessib, Dhia Kaffel, Kaouther Maatallah, Wafa Hamdi

Published in: European Journal of Pediatrics

Login to get access

Abstract

Blau syndrome is a rare genetic granulomatosis affecting children. It could be responsible for vision-threatening complications and articular deformation. Due to the rarity of this disease, there are no standardized guidelines for its management. This work aimed to provide an updated overview of the different therapeutic options for Blau syndrome. We conducted research in the PubMed database for the different treatments used in Blau syndrome patients, and we proposed a therapeutic algorithm for disease management. High doses of corticosteroids are considered as a bridging therapy in Blau syndrome. Methotrexate should be initiated if the patient has articular or ocular involvement. An anti-tumor necrosis factor α should be added for patients with uveitis or residual arthritis. If the patient remains symptomatic, a switch to another anti-tumor necrosis factor α is the best option. In non-responders to the first- and second-line biotherapies, a switch to an anti-interleukin 1, an anti-interleukin 6, or tofacitinib is necessary.
Conclusion: This article suggested an algorithm for the treatment of Blau syndrome. Other studies are necessary to confirm the efficacy of these treatments.
What is Known:
• Blau syndrome is a rare but severe granulomatosis that could be responsible for vision-threatening complications and articular deformation.
• Blau syndrome seems to be refractory to treatments.
What is New:
• High doses of corticosteroids are usually insufficient and should be considered only as a bridging therapy.
• Blau syndrome could be considered as a poor factor for uveitis, thus, an anti-tumor necrosis factor α should be initiated for patients with uveitis or with residual arthritis.
Literature
2.
go back to reference Takada S, Saito MK, Kambe N (2020) Blau syndrome: NOD2-related systemic autoinflammatory granulomatosis. G Ital Dermatol Venereol 155(5):537–541 PubMedCrossRef Takada S, Saito MK, Kambe N (2020) Blau syndrome: NOD2-related systemic autoinflammatory granulomatosis. G Ital Dermatol Venereol 155(5):537–541 PubMedCrossRef
3.
go back to reference Chiu B, Chan J, Das S, Alshamma Z, Sergi C (2019) Pediatric sarcoidosis: a review with emphasis on early onset and high-risk sarcoidosis and diagnostic challenges. Diagnostics (Basel) 9(4):160 PubMedCrossRef Chiu B, Chan J, Das S, Alshamma Z, Sergi C (2019) Pediatric sarcoidosis: a review with emphasis on early onset and high-risk sarcoidosis and diagnostic challenges. Diagnostics (Basel) 9(4):160 PubMedCrossRef
4.
go back to reference Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L (2012) Blau syndrome, clinical and genetic aspects. Autoimmun Rev 12(1):44–51 PubMedCrossRef Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L (2012) Blau syndrome, clinical and genetic aspects. Autoimmun Rev 12(1):44–51 PubMedCrossRef
5.
6.
go back to reference Okazaki F, Wakiguchi H, Korenaga Y, Nakamura T, Yasudo H, Uchi S et al (2021) A novel mutation in early-onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes. Pediatr Rheumatol Online J 19(1):18 PubMedPubMedCentralCrossRef Okazaki F, Wakiguchi H, Korenaga Y, Nakamura T, Yasudo H, Uchi S et al (2021) A novel mutation in early-onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes. Pediatr Rheumatol Online J 19(1):18 PubMedPubMedCentralCrossRef
7.
go back to reference Arakawa A, Kambe N, Nishikomori R, Tanabe A, Ueda M, Nishigori C et al (2021) NOD2 mutation-associated case with Blau syndrome triggered by BCG vaccination. Children (Basel) 8(2):117 PubMed Arakawa A, Kambe N, Nishikomori R, Tanabe A, Ueda M, Nishigori C et al (2021) NOD2 mutation-associated case with Blau syndrome triggered by BCG vaccination. Children (Basel) 8(2):117 PubMed
8.
go back to reference Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P et al (2015) Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology (Oxford) 54(6):1008–1016 PubMedCrossRef Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P et al (2015) Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology (Oxford) 54(6):1008–1016 PubMedCrossRef
9.
go back to reference Poline J, Bourrat E, Meinzer U (2020) Camptodactlyly in pediatric practice: Blau syndrome. J Pediatr 221:257–259 PubMedCrossRef Poline J, Bourrat E, Meinzer U (2020) Camptodactlyly in pediatric practice: Blau syndrome. J Pediatr 221:257–259 PubMedCrossRef
10.
go back to reference Poline J, Fogel O, Pajot C, Miceli-Richard C, Rybojad M, Galeotti C et al (2020) Early-onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndrome. J Eur Acad Dermatol Venereol 34(2):340–348 PubMedCrossRef Poline J, Fogel O, Pajot C, Miceli-Richard C, Rybojad M, Galeotti C et al (2020) Early-onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndrome. J Eur Acad Dermatol Venereol 34(2):340–348 PubMedCrossRef
11.
go back to reference Maccora I, Marrani E, Mastrolia MV, Abu-Rumeileh S, Maniscalco V, Fusco E et al (2021) Ocular involvement in monogenic autoinflammatory disease. Autoimmun Rev 20(11):102944 PubMedCrossRef Maccora I, Marrani E, Mastrolia MV, Abu-Rumeileh S, Maniscalco V, Fusco E et al (2021) Ocular involvement in monogenic autoinflammatory disease. Autoimmun Rev 20(11):102944 PubMedCrossRef
12.
go back to reference Saini SK, Rose CD (1996) Liver involvement in familial granulomatous arthritis (Blau syndrome). J Rheumatol 23(2):396–399 PubMed Saini SK, Rose CD (1996) Liver involvement in familial granulomatous arthritis (Blau syndrome). J Rheumatol 23(2):396–399 PubMed
13.
go back to reference Ting SS, Ziegler J, Fischer E (1998) Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr 133(3):450–452 PubMedCrossRef Ting SS, Ziegler J, Fischer E (1998) Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr 133(3):450–452 PubMedCrossRef
14.
go back to reference Jabs DA, Houk JL, Bias WB, Arnett FC (1985) Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 78(5):801–804 PubMedCrossRef Jabs DA, Houk JL, Bias WB, Arnett FC (1985) Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 78(5):801–804 PubMedCrossRef
15.
go back to reference Sinharay R, McKeown L, Phillips C, Li A, Duckworth A, Hall F et al (2021) First report of liver transplantation in Blau syndrome: the challenges faced in this rare granulomatous liver disease. Transpl Immunol 65:101378 PubMedCrossRef Sinharay R, McKeown L, Phillips C, Li A, Duckworth A, Hall F et al (2021) First report of liver transplantation in Blau syndrome: the challenges faced in this rare granulomatous liver disease. Transpl Immunol 65:101378 PubMedCrossRef
16.
go back to reference Wu D, Shen M (2018) Two Chinese pedigrees of Blau syndrome with thirteen affected members. Clin Rheumatol 37(1):265–270 PubMedCrossRef Wu D, Shen M (2018) Two Chinese pedigrees of Blau syndrome with thirteen affected members. Clin Rheumatol 37(1):265–270 PubMedCrossRef
17.
go back to reference Su J, Liu D (2021) Blau syndrome with pulmonary nodule in a child. Australas J Dermatol 62(2):217–220 PubMedCrossRef Su J, Liu D (2021) Blau syndrome with pulmonary nodule in a child. Australas J Dermatol 62(2):217–220 PubMedCrossRef
18.
go back to reference Sarens IL, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Chédeville G et al (2018) Blau Syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am J Ophthalmol 187:158–166 PubMedCrossRef Sarens IL, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Chédeville G et al (2018) Blau Syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am J Ophthalmol 187:158–166 PubMedCrossRef
19.
go back to reference Wu S, Zhong L, Sun Z, Zhu T, Song H, Sui R (2020) Ocular features in Chinese patients with Blau syndrome. Ocul Immunol Inflamm 28(1):79–85 PubMedCrossRef Wu S, Zhong L, Sun Z, Zhu T, Song H, Sui R (2020) Ocular features in Chinese patients with Blau syndrome. Ocul Immunol Inflamm 28(1):79–85 PubMedCrossRef
21.
go back to reference Jindal AK, Pilania RK, Suri D, Gupta A, Gattorno M, Ceccherini I et al (2021) A young female with early onset arthritis, uveitis, hepatic, and renal granulomas: a clinical tryst with Blau syndrome over 20 years and case-based review. Rheumatol Int 41(1):173–181 PubMedCrossRef Jindal AK, Pilania RK, Suri D, Gupta A, Gattorno M, Ceccherini I et al (2021) A young female with early onset arthritis, uveitis, hepatic, and renal granulomas: a clinical tryst with Blau syndrome over 20 years and case-based review. Rheumatol Int 41(1):173–181 PubMedCrossRef
22.
go back to reference Matsuda T, Kambe N, Takimoto-Ito R, Ueki Y, Nakamizo S, Saito MK et al (2022) Potential benefits of TNF targeting therapy in Blau syndrome, a NOD2-associated systemic autoinflammatory granulomatosis. Front Immunol 13:895765 PubMedPubMedCentralCrossRef Matsuda T, Kambe N, Takimoto-Ito R, Ueki Y, Nakamizo S, Saito MK et al (2022) Potential benefits of TNF targeting therapy in Blau syndrome, a NOD2-associated systemic autoinflammatory granulomatosis. Front Immunol 13:895765 PubMedPubMedCentralCrossRef
23.
go back to reference Nascimento H, Sousa JM, Fernández DG, Salomão GHA, Sato EH, Muccioli C et al (2018) Blau-Jabs syndrome in a tertiary ophthalmologic center. Ophthalmic Surg Lasers Imaging Retina 49(1):70–75 PubMedCrossRef Nascimento H, Sousa JM, Fernández DG, Salomão GHA, Sato EH, Muccioli C et al (2018) Blau-Jabs syndrome in a tertiary ophthalmologic center. Ophthalmic Surg Lasers Imaging Retina 49(1):70–75 PubMedCrossRef
24.
go back to reference Marín-Noriega MA, Muñoz-Ortiz J, Mosquera C, de-la-Torre A (2020) Ophthalmological treatment of early-onset sarcoidosis/Blau syndrome in a Colombian child: a case report. Am J Ophthalmol Case Rep 18:100714 Marín-Noriega MA, Muñoz-Ortiz J, Mosquera C, de-la-Torre A (2020) Ophthalmological treatment of early-onset sarcoidosis/Blau syndrome in a Colombian child: a case report. Am J Ophthalmol Case Rep 18:100714
25.
go back to reference PaÇ Kisaarslan A, SÖzerİ B, Şahİn N, Özdemİr ÇİÇek S, GÜndÜz Z, Demİrkaya E et al (2020) Blau syndrome and early-onset sarcoidosis: a six case series and review of the literature. Arch Rheumatol 35(1):117–127 PaÇ Kisaarslan A, SÖzerİ B, Şahİn N, Özdemİr ÇİÇek S, GÜndÜz Z, Demİrkaya E et al (2020) Blau syndrome and early-onset sarcoidosis: a six case series and review of the literature. Arch Rheumatol 35(1):117–127
26.
go back to reference Shetty AK, Gedalia A (1998) Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila) 37(12):707–717 PubMedCrossRef Shetty AK, Gedalia A (1998) Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila) 37(12):707–717 PubMedCrossRef
27.
go back to reference Millington GWM, Dobson J, Holden S, Waters G, Puvanachandra N, Close R et al (2019) Sporadic Blau syndrome treated with adalimumab. Clin Exp Dermatol 44(7):811–813 PubMedCrossRef Millington GWM, Dobson J, Holden S, Waters G, Puvanachandra N, Close R et al (2019) Sporadic Blau syndrome treated with adalimumab. Clin Exp Dermatol 44(7):811–813 PubMedCrossRef
28.
go back to reference Kumrah R, Pilania RK, Menia NK, Rawat A, Sharma J, Gupta A et al (2022) Blau syndrome: lessons learned in a tertiary care centre at Chandigarh. North India Front Immunol 13:932919 PubMedCrossRef Kumrah R, Pilania RK, Menia NK, Rawat A, Sharma J, Gupta A et al (2022) Blau syndrome: lessons learned in a tertiary care centre at Chandigarh. North India Front Immunol 13:932919 PubMedCrossRef
29.
go back to reference Chen J, Luo Y, Zhao M, Wu D, Yang Y, Zhang W et al (2019) Effective treatment of TNFα inhibitors in Chinese patients with Blau syndrome. Arthritis Res Ther 21(1):236 PubMedPubMedCentralCrossRef Chen J, Luo Y, Zhao M, Wu D, Yang Y, Zhang W et al (2019) Effective treatment of TNFα inhibitors in Chinese patients with Blau syndrome. Arthritis Res Ther 21(1):236 PubMedPubMedCentralCrossRef
30.
go back to reference Yasui K, Yashiro M, Tsuge M, Manki A, Takemoto K, Yamamoto M et al (2010) Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum 62(1):250–257 PubMedCrossRef Yasui K, Yashiro M, Tsuge M, Manki A, Takemoto K, Yamamoto M et al (2010) Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum 62(1):250–257 PubMedCrossRef
31.
go back to reference Wang W, Wang W, Zhong LQ, Li WD, Wu SJ, Song HM (2022) Thalidomide may be an effective drug for Blau syndrome: a case report. Ann Palliat Med 11(7):2538–2543 PubMedCrossRef Wang W, Wang W, Zhong LQ, Li WD, Wu SJ, Song HM (2022) Thalidomide may be an effective drug for Blau syndrome: a case report. Ann Palliat Med 11(7):2538–2543 PubMedCrossRef
32.
go back to reference Soper JR, Bonar SF, O’Sullivan DJ, McCredie J, Willert HG (2019) Thalidomide and neurotrophism. Skeletal Radiol 48(4):517–525 PubMedCrossRef Soper JR, Bonar SF, O’Sullivan DJ, McCredie J, Willert HG (2019) Thalidomide and neurotrophism. Skeletal Radiol 48(4):517–525 PubMedCrossRef
33.
go back to reference Lu L, Shen M, Jiang D, Li Y, Zheng X, Li Y et al (2018) Blau syndrome with good reponses to tocilizumab: a case report and focused literature review. Semin Arthritis Rheum 47(5):727–731 PubMedCrossRef Lu L, Shen M, Jiang D, Li Y, Zheng X, Li Y et al (2018) Blau syndrome with good reponses to tocilizumab: a case report and focused literature review. Semin Arthritis Rheum 47(5):727–731 PubMedCrossRef
34.
go back to reference Nagakura T, Wakiguchi H, Kubota T, Yamatou T, Yamasaki Y, Nonaka Y et al (2017) Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome. J Rheumatol 44(4):536–538 PubMedCrossRef Nagakura T, Wakiguchi H, Kubota T, Yamatou T, Yamasaki Y, Nonaka Y et al (2017) Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome. J Rheumatol 44(4):536–538 PubMedCrossRef
35.
go back to reference Matsuda T, Kambe N, Ueki Y, Kanazawa N, Izawa K, Honda Y et al (2020) Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis 79(11):1492–1499 PubMedCrossRef Matsuda T, Kambe N, Ueki Y, Kanazawa N, Izawa K, Honda Y et al (2020) Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis 79(11):1492–1499 PubMedCrossRef
36.
go back to reference Raiji VR, Miller MM, Jung LK (2011) Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 15(2):205–207 PubMedCrossRef Raiji VR, Miller MM, Jung LK (2011) Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 15(2):205–207 PubMedCrossRef
37.
go back to reference Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gómez J, Merino R (2013) Adalimumab therapy for refractory childhood uveitis. J AAPOS 17(5):456–459 PubMedCrossRef Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gómez J, Merino R (2013) Adalimumab therapy for refractory childhood uveitis. J AAPOS 17(5):456–459 PubMedCrossRef
38.
go back to reference Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V et al (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 65(2):513–518 PubMedPubMedCentralCrossRef Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V et al (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 65(2):513–518 PubMedPubMedCentralCrossRef
39.
go back to reference Caracseghi F, Izquierdo-Blasco J, Sanchez-Montanez A, Melendo-Perez S, Roig-Quilis M, Modesto C (2011) Etanercept-induced myelopathy in a pediatric case of blau syndrome. Case Rep Rheumatol 2011:134106 PubMed Caracseghi F, Izquierdo-Blasco J, Sanchez-Montanez A, Melendo-Perez S, Roig-Quilis M, Modesto C (2011) Etanercept-induced myelopathy in a pediatric case of blau syndrome. Case Rep Rheumatol 2011:134106 PubMed
40.
go back to reference Martin TM, Zhang Z, Kurz P, Rosé CD, Chen H, Lu H et al (2009) The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 60(2):611–618 PubMedPubMedCentralCrossRef Martin TM, Zhang Z, Kurz P, Rosé CD, Chen H, Lu H et al (2009) The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 60(2):611–618 PubMedPubMedCentralCrossRef
41.
go back to reference Godfrey MS, Friedman LN (2019) Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med 40(4):721–739 PubMedCrossRef Godfrey MS, Friedman LN (2019) Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. Clin Chest Med 40(4):721–739 PubMedCrossRef
42.
go back to reference Barbati F, Marrani E, Volpi B, Ferrara G, Lodi L, Mastrolia MV et al (2022) Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study. Eur J Pediatr 181(9):3439–3448 PubMedCrossRef Barbati F, Marrani E, Volpi B, Ferrara G, Lodi L, Mastrolia MV et al (2022) Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study. Eur J Pediatr 181(9):3439–3448 PubMedCrossRef
43.
go back to reference Zhang S, Cai Z, Mo X, Zeng H (2021) Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients. Pediatr Rheumatol Online J 19(1):160 PubMedPubMedCentralCrossRef Zhang S, Cai Z, Mo X, Zeng H (2021) Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients. Pediatr Rheumatol Online J 19(1):160 PubMedPubMedCentralCrossRef
44.
go back to reference Aróstegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P et al (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 56(11):3805–3813 PubMedCrossRef Aróstegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P et al (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 56(11):3805–3813 PubMedCrossRef
45.
go back to reference Lopalco G, Schiraldi S, Venerito V, Guerriero S, Iannone F (2020) Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. Mult Scler Relat Disord 42:102152 PubMedCrossRef Lopalco G, Schiraldi S, Venerito V, Guerriero S, Iannone F (2020) Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. Mult Scler Relat Disord 42:102152 PubMedCrossRef
46.
go back to reference Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):191–197 PubMedCrossRef Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):191–197 PubMedCrossRef
47.
go back to reference Maccora I, Abu Rumeileh S, Curci F, de Libero C, Marrani E, Mastrolia MV et al (2022) Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience. Front Pediatr 10:851453 PubMedPubMedCentralCrossRef Maccora I, Abu Rumeileh S, Curci F, de Libero C, Marrani E, Mastrolia MV et al (2022) Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience. Front Pediatr 10:851453 PubMedPubMedCentralCrossRef
48.
go back to reference Brunner HI, Wong R, Nys M, Kou TD, Dominique A, Martini A et al (2020) Abatacept: a review of the treatment of polyarticular-course juvenile idiopathic arthritis. Paediatr Drugs 22(6):653–672 PubMedCrossRef Brunner HI, Wong R, Nys M, Kou TD, Dominique A, Martini A et al (2020) Abatacept: a review of the treatment of polyarticular-course juvenile idiopathic arthritis. Paediatr Drugs 22(6):653–672 PubMedCrossRef
49.
go back to reference Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA (2021) JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80(7):865–875 PubMedCrossRef Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA (2021) JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80(7):865–875 PubMedCrossRef
50.
go back to reference Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, Sánchez-Bilbao L, Martín-Varillas JL, González-López E et al (2022) Clinical and immunological study of tofacitinib and baricitinib in refractory Blau syndrome: case report and literature review. Ther Adv Musculoskelet Dis 14:1759720X221093211 Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, Sánchez-Bilbao L, Martín-Varillas JL, González-López E et al (2022) Clinical and immunological study of tofacitinib and baricitinib in refractory Blau syndrome: case report and literature review. Ther Adv Musculoskelet Dis 14:1759720X221093211
51.
go back to reference Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken) 71(6):703–716 PubMedCrossRef Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken) 71(6):703–716 PubMedCrossRef
52.
go back to reference Foeldvari I, Maccora I, Petrushkin H, Rahman N, Anton J, de Boer J et al (2023) New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken) 75(5):975–982 PubMedCrossRef Foeldvari I, Maccora I, Petrushkin H, Rahman N, Anton J, de Boer J et al (2023) New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken) 75(5):975–982 PubMedCrossRef
Metadata
Title
Management of Blau syndrome: review and proposal of a treatment algorithm
Authors
Hanene Lassoued Ferjani
Lobna Kharrat
Dorra Ben Nessib
Dhia Kaffel
Kaouther Maatallah
Wafa Hamdi
Publication date
22-09-2023
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-023-05204-9